Introduction
Major depressive disorder is a common illness. According to the WHO major depressive disorder will be one of the leading causes of disability worldwide by 2020, second only to ischaemic heart disease (1) . The high level of disability associated with depression is mainly caused by it ' s chronic or recurrent course (2,3). To prevent chronicity, relapses or recurrences after remission has been achieved during treatment of the acute episode, guidelines recommend long-term treatment with antidepressants (AD) (4 -6) . Two recent meta-analyses based on a considerable number of placebo-controlled trials in which patients were randomized to either continuation of AD or placebo during the fi rst three months after remission, have shown that continuation treatment with AD signifi cantly decreases relapse rates within the fi rst three months after randomization (7, 8) . This evidence supports the recommendation for continuation treatment with AD during the fi rst months after remission to prevent relapse. Far less research has investigated the effi cacy of longer-term maintenance treatment for prevention of recurrence (7, 8) . Although guidelines also recommend maintenance treatment with AD for several years, or even lifelong, for patients with previous recurrences the scientifi c basis for these recommendations is meagre, since only few studies have addressed the effi cacy of AD in patients randomized more than three months after remission (4 -6,8) . For registration of an AD (e.g. by the European Agency for the Evaluation of Medicinal Products), the manufacturer is required to provide effi cacy data from placebo-controlled acute treatment studies as well as continuation studies lasting up to six months (http://www.emea.europa.eu/ pdfs/human/ewp/051897en.pdf).
The majority of patients with depression are treated in primary care (9). One may assume that treatment of depression might not be that different between primary and secondary care, but without proof we cannot simply extrapolate the guidelines from secondary care to primary care. In addition, some studies did fi nd, although small, differences between patients in primary and secondary care. For example, psychotic features and suicidality are less often present in primary care (10). Primary care patients with depression seem to be less accepting of treatment, possibly leading to a lower effectiveness (11). Furthermore, patients in primary care less often receive psychotherapy (12). As the majority of studies of long-term AD treatment have been carried out in secondary care, their generalizability to primary care remains uncertain (7, 8) .
We sought to investigate the current depression guideline recommendations on long-term treatment with AD in primary care in order to determine if the recommendations are supported by studies representative of the primary care population. This review, therefore, addressed the following questions:
1. What is, according to current guidelines, the recommended duration of treatment with AD after remission for patients with major depressive disorder treated in primary care? 2. Are these recommendations for long-term treatment with AD in primary care supported by evidence from the literature?
Methods

Guideline recommendations
For the fi rst question our aim was to collect current guidelines, from Europe and English-speaking countries in other parts of the world, which provided recommendations for primary care about AD treatment in major depressive disorders. Therefore, we searched PubMed, Cochrane, PsycInfo, Embase, Cinahl, and the National Guideline Clearinghouse as well as with the search machine Google with the keywords ' depression ' , ' guideline ' and ' treatment ' . In addition, we searched the website of WONCA for links to primary care organizations in European countries; on the websites of these organizations we searched for depression guidelines. We excluded guidelines that were based on other guidelines and guidelines over 10 years old.
Studies on effi cacy of long-term treatment with AD in primary care
For the second question, we used four systematic search strategies. In order to exclude the possibility that we might have missed articles with the chosen strategy, especially because not all primary care studies mentioned that they were performed in this setting, we did two additional searches in one database (PubMed) by adding the text word ' depression ' and without all search terms referring to ' primary care ' , respectively. Either search did not reveal any additional paper. Third, we used the so-called ' snowball method ' whereby we searched the reference lists of all retrieved articles for possible other relevant articles. Finally, we used Web of Science searching for articles citing the retrieved articles from our original search.
Data extraction
The search results were fi rst screened on title and abstract for studies on long-term treatment with AD of major depressive disorder in primary care. All retrieved articles were obtained and the full text articles were read using the inclusion criteria described earlier.
Studies in specifi c groups of depressed patients (e.g. post-stroke depression, post-myocardial infarction depression), in children (aged less than 18 years) or the elderly (aged above 65 years) were excluded because depression course and response to AD can be different in these patients (13 -15). We excluded duplicates after retrieval of full text articles, because of practical reasons. All searches were performed by the fi rst author, who also did most of the title and abstract screening. She consulted the other authors in case she doubted about an article. Eventual full text article selection and data extraction was done during a meeting with all authors.
Results
Guideline recommendations for long-term treatment with AD in primary care
We collected 13 depression guidelines specifi cally addressing or at least mentioning treatment of depression with AD in primary care. An overview of the recommendations in the guidelines for the longterm treatment with AD in primary care is found in Table I (4 -6,16 -25) . Although all guidelines recommended continuation treatment with AD after remission for all patients, recommendations for duration of continuation treatment varied from 4 to 12 months. Maintenance treatment of varying durations (between 1 year and lifelong) was recommended for patients at high risk of recurrence, which each guideline defi ned differently. Almost all cited references in guidelines were based on studies carried out in secondary or tertiary care settings; most of these studies randomized patients within three months after remission and the difference between antidepressant and placebo was already achieved within three months after randomization (4 -6,16 -25) . Relapse risk was 25% in the fi rst year after remission, 42% after two years, 60% after fi ve years and 50 -85% after 15 years (3,26). The risk of relapse or recurrence increased after each subsequent episode (26).
None of the guidelines specifi ed whether recommendations for primary care should be different than those for secondary care and no guideline referred specifi cally to any controlled study performed in primary care.
Studies on effi cacy of long-term treatment with AD in primary care
The database searches identifi ed a total of 716 titles, including duplicates, because titles were retrieved in ( n ϭ 99) and paroxetine ( n ϭ 98) during 24 weeks in patients with a major depressive episode. Only 91 patients (46.1%) completed the study, while remission was obtained in 35 patients (35%) receiving mirtazapine and 22 patients (22%) receiving paroxetine. After remission, in both groups 2 patients relapsed before the end of the study at 24 weeks. The authors did neither mention how many patients were actually followed after remission nor for how long (28).
The second study involved 1031 primary care patients with DSM-IV major depression who had been participants in another study (30) . All patients were treated with sertraline for 24 weeks, which resulted in remission in 59% of patients. Patients (including non-remitters and non-responders) were naturalistically followed-up for up to two years. During this follow-up, the general practitioner made all decisions about treatment. Depression outcome was compared for patients who were adherent to treatment with AD versus non-adherent patients. Overall relapse or recurrence rates were not statistically different between groups, but adherent patients (mean more than one database. Reference checking and the cited reference search rendered a total of 88 records. Screening titles and abstracts yielded 27 potentially relevant articles after removing duplicates (see Figure 1 ). Of these, 18 articles were excluded because they did not concern the effi cacy of long-term treatment with AD in primary care or did not have relapse risk as an outcome measure; two studies were not performed (solely) in primary care; and one article, which was the only study from primary care frequently referred to in guidelines, proved to be a retrospective case-note-audit conducted in primary care, not addressing the relationship between AD use and relapse (27). We were unable to acquire four articles. In summary, after reading the full-text articles, two publications remained (28,29). Neither of them was a placebo controlled study performed in primary care, which addressed the effi cacy of AD in the prevention of relapse or recurrence in major depressive disorder.
One study was an RCT involving 197 patients comparing the effi cacy and tolerability of mirtazapine no studies in which patients were randomized after three months of remission (8). Thus, it can be concluded that the recommendations for the use of antidepressants in continuation treatment (i.e. during the fi rst three to six months after remission to prevent relapse) are evidence based. However, good quality evidence is lacking for recommendations on the category of patients for whom maintenance treatment is appropriate, and on the duration of maintenance treatment. Furthermore, guideline recommendations for long-term treatment are only based on studies in patients treated in secondary care or specialized research settings and not for patients treated in primary care. Although one could argue that there are no strong arguments that recommendations on maintenance treatment with antidepressants in primary care should be different form secondary care, we conclude that they cannot be considered evidence-based. Hence, clinicians should be cautious with following the guidelines too strictly and instead may adjust the indication for long-term treatment to fi t each patient ' s need. Finally, we conclude that further studies on the long-term treatment with antidepressants in primary care are warranted.
Conclusion
While depression guidelines recommend long-term (maintenance) treatment with antidepressants for both primary and secondary care patients with recurrent depressive episodes, it remains unclear whether these recommendations apply for patients in primary care.
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Discussion
Our main fi ndings are that the available guidelines do not specify that recommendations in primary care might be different from recommendations in secondary care with respect to continuation and maintenance treatment with AD. Moreover, there is a paucity of research investigating the effi cacy of long-term treatment with antidepressants in primary care.
A limitation of this review is that we were unable to acquire all existing guidelines. Furthermore, we could not acquire all potentially interesting full text articles. Finally, we limited our search to articles published in the English language. The strength of this review is the comparison between guideline recommendations and evidence. Guidelines are used in everyday practice of primary care, and they are often thought to contain a high level of evidence. However, it is not always clear whether primary care guidelines are based on evidence from primary care.
Overall, guidelines recommend the continuation of treatment with AD for all patients for a period of four, nine or even 12 months. Maintenance treatment for a longer period, (i.e. between one year and lifelong) is recommended for patients at high risk of recurrence, which each guideline defi nes differently. However, the guidelines do not specify that recommendations are actually based on studies in secondary or tertiary care.
Our systematic search did not identify any placebocontrolled RCT to support the effi cacy of continuation or maintenance treatment with AD in primary care. The two studies we found provided only circumstantial evidence suggesting that long-term treatment with AD can reduce relapse or recurrence rates (28, 29) . This raises the question on which studies the guidelines base their ' level 1 ' evidence. Guidelines refer to many studies with respect to optimal duration of treatment with AD after having achieved remission. In their recent meta-analysis of 30 placebo-controlled RCTs on long-term treatment with tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs), Kaymaz et al. found a signifi cant relapse-reducing effect of antidepressants compared to placebo at three, six, nine, as well as 12 months of follow-up. However, they also showed that the difference between antidepressant and placebo was achieved within three months after randomization, while no additional reduction in risk was observed at further follow-up (8). With the exception of two very small trials including a total of 32 patients, there were For personal use only.
